SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-180854
Filing Date
2022-06-24
Accepted
2022-06-24 09:01:33
Documents
12
Period of Report
2022-06-23
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d307296d8k.htm   iXBRL 8-K 25786
  Complete submission text file 0001193125-22-180854.txt   147874

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA tptx-20220623.xsd EX-101.SCH 2879
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE tptx-20220623_lab.xml EX-101.LAB 17996
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tptx-20220623_pre.xml EX-101.PRE 11277
6 EXTRACTED XBRL INSTANCE DOCUMENT d307296d8k_htm.xml XML 3369
Mailing Address 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121
Business Address 10628 SCIENCE CENTER DRIVE, SUITE 200 SAN DIEGO CA 92121 858-926-5251
Turning Point Therapeutics, Inc. (Filer) CIK: 0001595893 (see all company filings)

IRS No.: 463826166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38871 | Film No.: 221037128
SIC: 2834 Pharmaceutical Preparations